Active Ingredient History

  • Now
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is active against wild-type and NNRTI-resistant HIV-1. Rilpivirine is a diarylpyrimidinethat inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.   NCATS

More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$27.1280 - $39.2748
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( cabotegravir, rilpivirine (edurant) - other name: cabotegravir and rilpivirine -extended release injectable suspension )
| | |
4-{[4-({4-[(e)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile | edurant | emtricitabine / rilpivirine hydrochloride / tenofovir alafenamide | emtricitabine / rilpivirine hydrochloride /tenofovir disoproxil fumarate | r-278474 | rilipivirine | rilpivirine | rilpivirine hcl | rilpivirine hydrochloride | rllpivirine | tmc278 | tmc-278 | tmc278-hydrochloride | tmc278la


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue